首页 > 最新文献

Allergy最新文献

英文 中文
Exposures in Indoor Air Affecting Health. 影响健康的室内空气暴露。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-04 DOI: 10.1111/all.70179
Maria Hartiala,Varpu Elenius,Alicia Aguado Pesquera,Silas Androulakis,Isabella Annesi-Maesano,Artur Badyda,Sicco Brandsma,Ioanna Chatziprodromidou,Goran Gajski,Judith Garcia-Aymerich,Chiara Giorio,Timo Hugg,Jouni J K Jaakkola,Sarah Koch,Pim E G Leonards,Angeliki Matrali,Lisa Melymuk,Natalie Mueller,Adam Muszyński,Jet Opbroek,Inês Paciência,Spyros N Pandis,Sofya Pozdniakova,Aino K Rantala,Sandra Rodríguez Sufuentes,Linda Schenk,Eva Sugeng,Adrià Sunyer-Caldú,Apostolos Vantarakis,Alexander Zherebker,Ernesto Alfaro-Moreno,Pernilla Bohlin Nizzetto,José Fermoso Dominguez,Stylianos Karatzas,Francesco Mureddu,Heidi Salonen,Nikolaos Papadopoulos,Tuomas Jartti,
Indoor air quality (IAQ) is influenced by a wide range of chemical, biological and physical agents that can negatively impact physical, immunological and mental health. Adverse health effects depend on the type and concentration of pollutants, duration of exposure, and individual susceptibility. The availability of data on IAQ is limited, as are standardized approaches for evaluating its health impact. This expert review aims to describe the most important indoor air determinants affecting health, and present the IDEAL cluster, which comprises seven EU-funded scientific projects on the topic of IAQ and human health. Across the IDEAL projects, knowledge is generated on exposure to a wide range of indoor air pollutants, including well-known hazards and more explorative chemical and microbiological determinants. The projects will also contribute to the implementation of low-cost and/or real-time sensors on IAQ, as well as advanced chemical and microbiological analyses, and evaluate various interventions to improve IAQ. Several of them focus on particularly vulnerable groups. Raising public awareness and implementing measures to reduce pollutant levels are essential for safeguarding health, particularly in urban areas with elevated pollution levels.
室内空气质量受到一系列化学、生物和物理因素的影响,这些因素会对身体、免疫和精神健康产生负面影响。对健康的不利影响取决于污染物的类型和浓度、接触时间和个人易感性。关于室内空气质量的数据有限,评价其健康影响的标准化方法也有限。本专家审查的目的是描述影响健康的最重要的室内空气决定因素,并介绍IDEAL组,其中包括七个欧盟资助的关于室内空气质量和人类健康主题的科学项目。在IDEAL项目中,关于暴露于各种室内空气污染物的知识产生了,包括众所周知的危害和更多探索性的化学和微生物决定因素。这些项目还将有助于对室内空气质量实施低成本和/或实时传感器,以及先进的化学和微生物分析,并评估各种改善室内空气质量的干预措施。其中有几个重点关注特别脆弱的群体。提高公众认识和采取措施降低污染物水平对于保障健康至关重要,特别是在污染水平较高的城市地区。
{"title":"Exposures in Indoor Air Affecting Health.","authors":"Maria Hartiala,Varpu Elenius,Alicia Aguado Pesquera,Silas Androulakis,Isabella Annesi-Maesano,Artur Badyda,Sicco Brandsma,Ioanna Chatziprodromidou,Goran Gajski,Judith Garcia-Aymerich,Chiara Giorio,Timo Hugg,Jouni J K Jaakkola,Sarah Koch,Pim E G Leonards,Angeliki Matrali,Lisa Melymuk,Natalie Mueller,Adam Muszyński,Jet Opbroek,Inês Paciência,Spyros N Pandis,Sofya Pozdniakova,Aino K Rantala,Sandra Rodríguez Sufuentes,Linda Schenk,Eva Sugeng,Adrià Sunyer-Caldú,Apostolos Vantarakis,Alexander Zherebker,Ernesto Alfaro-Moreno,Pernilla Bohlin Nizzetto,José Fermoso Dominguez,Stylianos Karatzas,Francesco Mureddu,Heidi Salonen,Nikolaos Papadopoulos,Tuomas Jartti, ","doi":"10.1111/all.70179","DOIUrl":"https://doi.org/10.1111/all.70179","url":null,"abstract":"Indoor air quality (IAQ) is influenced by a wide range of chemical, biological and physical agents that can negatively impact physical, immunological and mental health. Adverse health effects depend on the type and concentration of pollutants, duration of exposure, and individual susceptibility. The availability of data on IAQ is limited, as are standardized approaches for evaluating its health impact. This expert review aims to describe the most important indoor air determinants affecting health, and present the IDEAL cluster, which comprises seven EU-funded scientific projects on the topic of IAQ and human health. Across the IDEAL projects, knowledge is generated on exposure to a wide range of indoor air pollutants, including well-known hazards and more explorative chemical and microbiological determinants. The projects will also contribute to the implementation of low-cost and/or real-time sensors on IAQ, as well as advanced chemical and microbiological analyses, and evaluate various interventions to improve IAQ. Several of them focus on particularly vulnerable groups. Raising public awareness and implementing measures to reduce pollutant levels are essential for safeguarding health, particularly in urban areas with elevated pollution levels.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"7 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145663943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Conjugate Vaccine Targeting Human IgE for Long-Term Prevention of Anaphylaxis. 长期预防过敏性反应的人IgE结合疫苗的研制。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-04 DOI: 10.1111/all.70099
Vincent Serra,Laurent L Reber
{"title":"Development of a Conjugate Vaccine Targeting Human IgE for Long-Term Prevention of Anaphylaxis.","authors":"Vincent Serra,Laurent L Reber","doi":"10.1111/all.70099","DOIUrl":"https://doi.org/10.1111/all.70099","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"157 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Questionnaire Survey on Loquat-Induced Oral Allergy Syndrome in School Children in Yamanashi, Japan. 日本山梨县学童枇杷致口腔过敏综合征问卷调查
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-03 DOI: 10.1111/all.70177
Ayumi Shimamura,Reiji Kojima,Hiroki Ishii,Tomokazu Matsuoka,Hisatake Ikeda,Daiju Sakurai
{"title":"Questionnaire Survey on Loquat-Induced Oral Allergy Syndrome in School Children in Yamanashi, Japan.","authors":"Ayumi Shimamura,Reiji Kojima,Hiroki Ishii,Tomokazu Matsuoka,Hisatake Ikeda,Daiju Sakurai","doi":"10.1111/all.70177","DOIUrl":"https://doi.org/10.1111/all.70177","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"57 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice 新出现的风险:鼻内锡加重人类和小鼠的过敏性鼻炎
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-02 DOI: 10.1111/all.70180
Delgama A. S. M. Nishadhi, Shogo Sumiya, Akira Tazaki, Takumi Kagawa, Mohamed Abdelmoneim, Masafumi Sakashita, Kazuhiro Ogi, Shigeharu Fujieda, Shinichi Iwasaki, Masashi Kato
{"title":"Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice","authors":"Delgama A. S. M. Nishadhi, Shogo Sumiya, Akira Tazaki, Takumi Kagawa, Mohamed Abdelmoneim, Masafumi Sakashita, Kazuhiro Ogi, Shigeharu Fujieda, Shinichi Iwasaki, Masashi Kato","doi":"10.1111/all.70180","DOIUrl":"https://doi.org/10.1111/all.70180","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"25 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments. 变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南-2024-2025修订:第一部分鼻内治疗指南。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-01 DOI: 10.1111/all.70131
Bernardo Sousa-Pinto,Jean Bousquet,Rafael José Vieira,Holger J Schünemann,Torsten Zuberbier,Antonio Bognanni,Alkis Togias,Boleslaw Samolinski,Arunas Valiulis,Sian Williams,Anna Bedbrook,Wienczyslawa Czarlewski,Maria Jose Torres,Mohamed H Shamji,Mário Morais-Almeida,G Walter Canonica,Leticia de Las Vecillas,Mark S Dykewicz,Cristina Jacomelli,Ludger Klimek,Lucas Leemann,Olga Lourenço,Yuliia Palamarchuk,Nikolaos G Papadopoulos,Ana Margarida Pereira,Marine Savouré,Sanna K Toppila-Salmi,Maria Teresa Ventura,Juan José Yepes-Nuñez,Alvaro A Cruz,Giorgio Ciprandi,Bilun Gemicioglu,Mattia Giovannini,Brigita Gradauskiene,Tuomas Jartti,Miloš Jeseňák,Piotr Kuna,Violeta Kvedariene,Désirée E Larenas-Linnemann,Amir Ha Latiff,Yousser Mohammad,Ken Ohta,Padukudru A Mahesh,Isabella Pali-Schöll,Oliver Pfaar,Frederico S Regateiro,Nicolas Roche,Luís Taborda-Barata,Charlotte Suppli Ulrik,Marylin Valentin Rostan,Giovanni Viegi,Luo Zhang,Tari Haahtela,Ivan Cherrez-Ojeda,Juan Carlos Ivancevich,Nikolai Khaltaev,Arzu Yorgancioglu,Baharudin Abdullah,Mona Al-Ahmad,Maryam Ali Al-Nesf,Rita Amaral,Julijana Asllani,Karl-C Bergmann,Jonathan A Bernstein,Michael S Blaiss,Fulvio Braido,Paulo Camargos,Pedro Carreiro-Martins,Thomas Casale,Lorenzo Cecchi,Alessandro Fiocchi,Antonio F M Giuliano,George Christoff,Ieva Cirule,Jaime Correia de Sousa,Elisio M Costa,Stefano Del Giacco,Philippe Devillier,Dejan Dokic,Elham Hossny,Tomohisa Iinuma,Carla Irani,Zhanat Ispayeva,Kaja Julge,Igor Kaidashev,Kazi S Bennoor,Helga Kraxner,Inger Kull,Marek Kulus,Maciej Kupczyk,Andriy Kurchenko,Stefania La Grutta,Neven Miculinic,Lan Le Thi Tuyet,Michael Makris,Branislava Milenkovic,Sang Min Lee,Stephen Montefort,Andre Moreira,Joaquim Mullol,Rachel Nadif,Alla Nakonechna,Hugo E Neffen,Marek Niedoszytko,Dieudonné Nyembue,Robyn E O'Hehir,Ismail Ogulur,Yoshitaka Okamoto,Heidi Olze,Oscar Palomares,Petr Panzner,Vincenzo Patella,Ruby Pawankar,Constantinos Pitsios,Todor A Popov,Francesca Puggioni,Santiago Quirce,Agné Ramonaité,Marysia Recto,Maria Susana Repka-Ramirez,Graham Roberts,Karla Robles-Velasco,Menachem Rottem,Marianella Salapatas,Joaquin Sastre,Nicola Scichilone,Juan-Carlos Sisul,Dirceu Solé,Manuel E Soto-Martinez,Milan Sova,Pongsakorn Tantilipikorn,Ana Todo-Bom,Vladyslav Tsaryk,Ioanna Tsiligianni,Marilyn Urrutia-Pereira,Erkka Valovirta,Tuula Vasankari,Dana Wallace,De Yun Wang,Margitta Worm,Osman M Yusuf,Mihaela Zidarn,Sara Gil-Mata,Manuel Marques-Cruz,Bassam Mahboub,Ignacio J Ansotegui,Antonino Romano,Werner Aberer,Maria Cristina Artesani,Elena Azzolini,Bruno Barreto,Joan Bartra,Sven Becker,Bianca Beghe,Attilio Boner,Ewa Borowiack,Jacques Bouchard,Melisande Bourgoin-Heck,Luisa Brussino,Roland Buhl,José Antonio Castillo-Vizuete,Denis Charpin,Niels H Chavannes,Marta Chełmińska,Lei Cheng,Ekaterine Chkhartishvili,Seong H Cho,Herberto Jose Chong-Neto,Deepa Choudhury,Derek K Chu,Cemal Cingi,Enrico Compalati,Raquel Albuquerque Costa,Olga Mariana Cunha,Biljana Cvetkovski,Victoria Cardona-Dahl,Gennaro D'Amato,Janet Davies,Danilo Di Bona,Sandra N Gonzalez Diaz,Maria V Dimou,Maria Doulaptsi,Renato Ferreira-da-Silva,Radoslaw Gawlik,Mario Calvo-Gil,Ozlem Goksel,Maximiliano R Gómez,Maia Gotua,Christos Grigoreas,Ineta Grisle,Maria Antonieta Guzman,Rachel House Tan,Michael Hyland,Despo Ierodiakonou,Aspasia Karavelia,Paul Keith,Marta Kisiel,Tanja Soklic Kosak,Mitja Kosnik,Ilgim Vardaloglu Koyuncu,Vicky Kritikos,Justyna Litynska,Carlo Lombardi,Gilles Louis,Matteo Martini,Cem Meço,Eris Mesonjesi,Florin Mihaltan,Marcin Moniuszko,Robert N Naclerio,Kari C Nadeau,Sophia Neisinger,Markus Ollert,Michal Ordak,Giovanni Paoletti,Hae-Sim Park,Elena Parmelli,Edgar Arturo Perdomo-Flores,José Miguel Fuentes Pérez,Nhan Pham-Thi,Emmanuel Prokopakis,Inês Ribeiro-Vaz,Giovanni Rolla,Jan Romantowski,Philippe Rombaux,Philip W Rouadi,Maia Rukhadze,Dermot Ryan,Ewelina Sadowska,Daiju Sakurai,Laila Salameh,Faradiba Serpa Sarquis,Elie Serrano,Jane Da Silva,Michael Soyka,Krzysztof Specjalski,Vesna Tomic-Spiric,Katarina Stevanovic,Abirami Subramaniam,Maria Do Ceu Teixeira,Tuuli Thomander,Martina Vachova,Marianne van Hage,Pakit Vichyanond,Martin Wagenmann,Fanny Wai San Ko,Pascal Werminghaus,Paraskevi Vicky Xepapadaki,Yi-Kui Xiang,Qintai Yang,Daniela Rivero Yeverino,Jaron Zuberbier,João A Fonseca
BACKGROUNDAllergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024-2025). This manuscript presents the ARIA 2024-2025 recommendations for intranasal treatments, one of the mainstays for AR management.METHODSThe ARIA 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.RESULTSEleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications-most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants-or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.CONCLUSIONThis ARIA 2024-2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.
变应性鼻炎(AR)影响生活质量、工作和学习效率。在过去几年中,来自移动健康数据的重要证据使人们对AR有了更好的了解。这些进展促使eaaci批准了变应性鼻炎及其对哮喘的影响(ARIA)指南(ARIA 2024-2025)的更新。本文介绍了ARIA 2024-2025关于鼻内治疗的建议,鼻内治疗是AR管理的主要支柱之一。方法:ARIA 2024-2025指南小组根据推荐、评估、发展和评价(GRADE)证据到决策框架的分级发布了建议。专家组的判断和建议采用了若干证据来源,包括系统审查、对移动健康和药物警戒数据的评估,以及对成本专家的调查。结果针对AR鼻内治疗的16个指南问题进行了优先排序,并给出了建议。总的来说,这些问题涉及到不同种类的鼻内药物的选择——最值得注意的是,鼻内皮质类固醇(INCS)、抗组胺药(INAH)、INAH+INCS和减充血剂的固定组合——或者在每一类药物中不同的个体药物之间的选择。以前的ARIA指南中没有评估四个问题,而对于其他三个问题,建议的力度或方向发生了变化。总的来说,建议使用INAH+INCS而不是INAH或INCS和INCS而不是INAH。结论:ARIA 2024-2025文章支持患者、其护理人员和医疗保健专业人员选择鼻内治疗。然而,关于AR治疗的决定应考虑疾病的临床变异性、患者的价值观和药物的可负担性。
{"title":"Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.","authors":"Bernardo Sousa-Pinto,Jean Bousquet,Rafael José Vieira,Holger J Schünemann,Torsten Zuberbier,Antonio Bognanni,Alkis Togias,Boleslaw Samolinski,Arunas Valiulis,Sian Williams,Anna Bedbrook,Wienczyslawa Czarlewski,Maria Jose Torres,Mohamed H Shamji,Mário Morais-Almeida,G Walter Canonica,Leticia de Las Vecillas,Mark S Dykewicz,Cristina Jacomelli,Ludger Klimek,Lucas Leemann,Olga Lourenço,Yuliia Palamarchuk,Nikolaos G Papadopoulos,Ana Margarida Pereira,Marine Savouré,Sanna K Toppila-Salmi,Maria Teresa Ventura,Juan José Yepes-Nuñez,Alvaro A Cruz,Giorgio Ciprandi,Bilun Gemicioglu,Mattia Giovannini,Brigita Gradauskiene,Tuomas Jartti,Miloš Jeseňák,Piotr Kuna,Violeta Kvedariene,Désirée E Larenas-Linnemann,Amir Ha Latiff,Yousser Mohammad,Ken Ohta,Padukudru A Mahesh,Isabella Pali-Schöll,Oliver Pfaar,Frederico S Regateiro,Nicolas Roche,Luís Taborda-Barata,Charlotte Suppli Ulrik,Marylin Valentin Rostan,Giovanni Viegi,Luo Zhang,Tari Haahtela,Ivan Cherrez-Ojeda,Juan Carlos Ivancevich,Nikolai Khaltaev,Arzu Yorgancioglu,Baharudin Abdullah,Mona Al-Ahmad,Maryam Ali Al-Nesf,Rita Amaral,Julijana Asllani,Karl-C Bergmann,Jonathan A Bernstein,Michael S Blaiss,Fulvio Braido,Paulo Camargos,Pedro Carreiro-Martins,Thomas Casale,Lorenzo Cecchi,Alessandro Fiocchi,Antonio F M Giuliano,George Christoff,Ieva Cirule,Jaime Correia de Sousa,Elisio M Costa,Stefano Del Giacco,Philippe Devillier,Dejan Dokic,Elham Hossny,Tomohisa Iinuma,Carla Irani,Zhanat Ispayeva,Kaja Julge,Igor Kaidashev,Kazi S Bennoor,Helga Kraxner,Inger Kull,Marek Kulus,Maciej Kupczyk,Andriy Kurchenko,Stefania La Grutta,Neven Miculinic,Lan Le Thi Tuyet,Michael Makris,Branislava Milenkovic,Sang Min Lee,Stephen Montefort,Andre Moreira,Joaquim Mullol,Rachel Nadif,Alla Nakonechna,Hugo E Neffen,Marek Niedoszytko,Dieudonné Nyembue,Robyn E O'Hehir,Ismail Ogulur,Yoshitaka Okamoto,Heidi Olze,Oscar Palomares,Petr Panzner,Vincenzo Patella,Ruby Pawankar,Constantinos Pitsios,Todor A Popov,Francesca Puggioni,Santiago Quirce,Agné Ramonaité,Marysia Recto,Maria Susana Repka-Ramirez,Graham Roberts,Karla Robles-Velasco,Menachem Rottem,Marianella Salapatas,Joaquin Sastre,Nicola Scichilone,Juan-Carlos Sisul,Dirceu Solé,Manuel E Soto-Martinez,Milan Sova,Pongsakorn Tantilipikorn,Ana Todo-Bom,Vladyslav Tsaryk,Ioanna Tsiligianni,Marilyn Urrutia-Pereira,Erkka Valovirta,Tuula Vasankari,Dana Wallace,De Yun Wang,Margitta Worm,Osman M Yusuf,Mihaela Zidarn,Sara Gil-Mata,Manuel Marques-Cruz,Bassam Mahboub,Ignacio J Ansotegui,Antonino Romano,Werner Aberer,Maria Cristina Artesani,Elena Azzolini,Bruno Barreto,Joan Bartra,Sven Becker,Bianca Beghe,Attilio Boner,Ewa Borowiack,Jacques Bouchard,Melisande Bourgoin-Heck,Luisa Brussino,Roland Buhl,José Antonio Castillo-Vizuete,Denis Charpin,Niels H Chavannes,Marta Chełmińska,Lei Cheng,Ekaterine Chkhartishvili,Seong H Cho,Herberto Jose Chong-Neto,Deepa Choudhury,Derek K Chu,Cemal Cingi,Enrico Compalati,Raquel Albuquerque Costa,Olga Mariana Cunha,Biljana Cvetkovski,Victoria Cardona-Dahl,Gennaro D'Amato,Janet Davies,Danilo Di Bona,Sandra N Gonzalez Diaz,Maria V Dimou,Maria Doulaptsi,Renato Ferreira-da-Silva,Radoslaw Gawlik,Mario Calvo-Gil,Ozlem Goksel,Maximiliano R Gómez,Maia Gotua,Christos Grigoreas,Ineta Grisle,Maria Antonieta Guzman,Rachel House Tan,Michael Hyland,Despo Ierodiakonou,Aspasia Karavelia,Paul Keith,Marta Kisiel,Tanja Soklic Kosak,Mitja Kosnik,Ilgim Vardaloglu Koyuncu,Vicky Kritikos,Justyna Litynska,Carlo Lombardi,Gilles Louis,Matteo Martini,Cem Meço,Eris Mesonjesi,Florin Mihaltan,Marcin Moniuszko,Robert N Naclerio,Kari C Nadeau,Sophia Neisinger,Markus Ollert,Michal Ordak,Giovanni Paoletti,Hae-Sim Park,Elena Parmelli,Edgar Arturo Perdomo-Flores,José Miguel Fuentes Pérez,Nhan Pham-Thi,Emmanuel Prokopakis,Inês Ribeiro-Vaz,Giovanni Rolla,Jan Romantowski,Philippe Rombaux,Philip W Rouadi,Maia Rukhadze,Dermot Ryan,Ewelina Sadowska,Daiju Sakurai,Laila Salameh,Faradiba Serpa Sarquis,Elie Serrano,Jane Da Silva,Michael Soyka,Krzysztof Specjalski,Vesna Tomic-Spiric,Katarina Stevanovic,Abirami Subramaniam,Maria Do Ceu Teixeira,Tuuli Thomander,Martina Vachova,Marianne van Hage,Pakit Vichyanond,Martin Wagenmann,Fanny Wai San Ko,Pascal Werminghaus,Paraskevi Vicky Xepapadaki,Yi-Kui Xiang,Qintai Yang,Daniela Rivero Yeverino,Jaron Zuberbier,João A Fonseca","doi":"10.1111/all.70131","DOIUrl":"https://doi.org/10.1111/all.70131","url":null,"abstract":"BACKGROUNDAllergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024-2025). This manuscript presents the ARIA 2024-2025 recommendations for intranasal treatments, one of the mainstays for AR management.METHODSThe ARIA 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs.RESULTSEleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications-most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants-or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH.CONCLUSIONThis ARIA 2024-2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"25 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heat-Not-Burn Tobacco Aerosols Induce Immune Dysregulation and Barrier Disruption Comparable to Conventional Cigarettes. 与传统香烟相比,加热不燃烧烟草气溶胶可诱导免疫失调和屏障破坏。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-12-01 DOI: 10.1111/all.70174
Dilara Karaguzel,Alicja Walewska,Basak Ezgi Sarac,Marlena Tynecka,Kinga Bondarczuk,Agnieszka Tarasik,Dariusz Kisiel,Karolina Partyk,Damian Pogodziński,Bartosz Hanczaruk,Alicja Toczydlowska,Cagla Bicakci,Doga Oztabak,Magdalena Niemira,Adam Kretowski,Marlena Dubatowka,Natalia Ogrodnik,Malgorzata Chlabicz,Pawel Sowa,Karol Kaminski,Marcin Moniuszko,Andrzej Eljaszewicz,Cagatay Karaaslan
BACKGROUNDHeat-not-burn (HnB) tobacco products are marketed as a safer alternative to conventional cigarettes (CC), yet their health effects remain controversial, largely based on industry-funded studies. We aimed to assess lung function in HnB and CC users and examine the mechanistic effects of HnB exposure using animal and in vitro models.METHODSSpirometry data from 650 non-smokers (NS), 293 CC smokers, and 49 HnB users enrolled in the Bialystok-PLUS cohort were analyzed. To investigate underlying mechanisms, a whole-body mouse exposure model was performed with HnB aerosol or 3R4F cigarette smoke, assessing lung transcriptomic profiles (by means of RNA sequencing), lung inflammation (by flow cytometry and histochemical staining), and barrier integrity (by using immunofluorescent staining). Moreover, an in vitro ALI-culture model of human airway epithelial cells was used to validate the mouse experiments. The effect of HnB and CC was assessed through cytotoxic effect (MTT and LDH), inflammatory responses (cytokine release by ELISA), and tight junction proteins (immunofluorescence staining).RESULTSpirometric analysis (FEV1, FVC, VC) revealed no significant overall differences in lung function among HnB users, CC smokers, and non-smokers (NS) in the unadjusted comparison. However, subgroup analyses showed that younger (< 45 years) HnB users and those with shorter smoking histories (< 20 years) already exhibited significantly lower FEV1, FVC, and VC compared to NS and CC smokers. After adjustment for age and smoking-related covariates, HnB users displayed modest but significant reductions in static FEV1 and FVC relative to NS, while no adjusted differences were detected between HnB and CC groups, indicating comparable baseline ventilatory function. Both exposures in mice increased eosinophils and B cell counts by ~2-fold, while decreasing ST2+ CD4+ T cells over 80%, and induced epithelial apoptosis. HnB aerosol selectively reduced basophils by almost 50%. Both HnB and CC exposure in mice caused significant epithelial damage and impaired airway barrier function, evidenced by a ~60% reduction in ZO-1. Transcriptomic analysis revealed that CC smoke triggered a robust inflammatory gene response, whereas HnB aerosol predominantly altered metabolic pathways. In vitro, barrier function was impaired under both conditions, but cytokine secretion increased only after CC smoke exposure.CONCLUSIONDespite different molecular impacts, HnB aerosol exposure induces a level of airway epithelial injury and immune cell infiltration comparable to CC smoke. Our findings challenged the narrative of HnB products being a harmless alternative and highlight their potential to cause significant lung pathology.
加热不燃烧(HnB)烟草产品作为一种比传统香烟(CC)更安全的替代品在市场上销售,但它们对健康的影响仍然存在争议,这主要是基于行业资助的研究。我们的目的是评估HnB和CC使用者的肺功能,并通过动物和体外模型检查HnB暴露的机制影响。方法分析Bialystok-PLUS队列中650名非吸烟者(NS)、293名CC吸烟者和49名HnB使用者的肺活量测定数据。为了研究潜在的机制,研究人员对HnB气溶胶或3R4F香烟烟雾进行了小鼠全身暴露模型,评估了肺部转录组学特征(通过RNA测序)、肺部炎症(通过流式细胞术和组织化学染色)和屏障完整性(通过免疫荧光染色)。此外,我们还建立了体外培养的人气道上皮细胞模型来验证小鼠实验。通过细胞毒作用(MTT和LDH)、炎症反应(ELISA检测细胞因子释放)和紧密连接蛋白(免疫荧光染色)评估HnB和CC的作用。结果肺功能分析(FEV1, FVC, VC)显示,在未调整的比较中,HnB使用者、CC吸烟者和非吸烟者(NS)的肺功能无显著性差异。然而,亚组分析显示,与NS和CC吸烟者相比,年轻(< 45岁)的HnB使用者和吸烟史较短(< 20年)的人已经表现出明显较低的FEV1、FVC和VC。在调整了年龄和吸烟相关的协变量后,HnB使用者相对于NS显示出适度但显著的静态FEV1和FVC降低,而在HnB组和CC组之间没有检测到调整后的差异,表明基线通气功能相当。这两种暴露均使小鼠嗜酸性粒细胞和B细胞计数增加约2倍,而ST2+ CD4+ T细胞减少80%以上,并诱导上皮细胞凋亡。HnB气溶胶选择性地减少了近50%的嗜碱性粒细胞。小鼠暴露于HnB和CC均可引起明显的上皮损伤和气道屏障功能受损,ZO-1减少约60%。转录组学分析显示,CC烟雾引发了强烈的炎症基因反应,而HnB气溶胶主要改变了代谢途径。在体外,两种条件下屏障功能均受损,但细胞因子分泌仅在CC烟雾暴露后增加。结论尽管分子影响不同,但HnB气溶胶暴露诱导的气道上皮损伤和免疫细胞浸润水平与CC烟雾相当。我们的研究结果挑战了HnB产品是一种无害的替代品的叙述,并强调了它们引起重大肺部病理的潜力。
{"title":"Heat-Not-Burn Tobacco Aerosols Induce Immune Dysregulation and Barrier Disruption Comparable to Conventional Cigarettes.","authors":"Dilara Karaguzel,Alicja Walewska,Basak Ezgi Sarac,Marlena Tynecka,Kinga Bondarczuk,Agnieszka Tarasik,Dariusz Kisiel,Karolina Partyk,Damian Pogodziński,Bartosz Hanczaruk,Alicja Toczydlowska,Cagla Bicakci,Doga Oztabak,Magdalena Niemira,Adam Kretowski,Marlena Dubatowka,Natalia Ogrodnik,Malgorzata Chlabicz,Pawel Sowa,Karol Kaminski,Marcin Moniuszko,Andrzej Eljaszewicz,Cagatay Karaaslan","doi":"10.1111/all.70174","DOIUrl":"https://doi.org/10.1111/all.70174","url":null,"abstract":"BACKGROUNDHeat-not-burn (HnB) tobacco products are marketed as a safer alternative to conventional cigarettes (CC), yet their health effects remain controversial, largely based on industry-funded studies. We aimed to assess lung function in HnB and CC users and examine the mechanistic effects of HnB exposure using animal and in vitro models.METHODSSpirometry data from 650 non-smokers (NS), 293 CC smokers, and 49 HnB users enrolled in the Bialystok-PLUS cohort were analyzed. To investigate underlying mechanisms, a whole-body mouse exposure model was performed with HnB aerosol or 3R4F cigarette smoke, assessing lung transcriptomic profiles (by means of RNA sequencing), lung inflammation (by flow cytometry and histochemical staining), and barrier integrity (by using immunofluorescent staining). Moreover, an in vitro ALI-culture model of human airway epithelial cells was used to validate the mouse experiments. The effect of HnB and CC was assessed through cytotoxic effect (MTT and LDH), inflammatory responses (cytokine release by ELISA), and tight junction proteins (immunofluorescence staining).RESULTSpirometric analysis (FEV1, FVC, VC) revealed no significant overall differences in lung function among HnB users, CC smokers, and non-smokers (NS) in the unadjusted comparison. However, subgroup analyses showed that younger (< 45 years) HnB users and those with shorter smoking histories (< 20 years) already exhibited significantly lower FEV1, FVC, and VC compared to NS and CC smokers. After adjustment for age and smoking-related covariates, HnB users displayed modest but significant reductions in static FEV1 and FVC relative to NS, while no adjusted differences were detected between HnB and CC groups, indicating comparable baseline ventilatory function. Both exposures in mice increased eosinophils and B cell counts by ~2-fold, while decreasing ST2+ CD4+ T cells over 80%, and induced epithelial apoptosis. HnB aerosol selectively reduced basophils by almost 50%. Both HnB and CC exposure in mice caused significant epithelial damage and impaired airway barrier function, evidenced by a ~60% reduction in ZO-1. Transcriptomic analysis revealed that CC smoke triggered a robust inflammatory gene response, whereas HnB aerosol predominantly altered metabolic pathways. In vitro, barrier function was impaired under both conditions, but cytokine secretion increased only after CC smoke exposure.CONCLUSIONDespite different molecular impacts, HnB aerosol exposure induces a level of airway epithelial injury and immune cell infiltration comparable to CC smoke. Our findings challenged the narrative of HnB products being a harmless alternative and highlight their potential to cause significant lung pathology.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"151 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Allergens Approved by the WHO/IUIS Allergen Nomenclature Sub-Committee in 2021-2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report. WHO/IUIS过敏原命名小组委员会在2021-2024年批准的新过敏原及其对未来诊断、监管和研究的意义EAACI工作小组报告。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-11-29 DOI: 10.1111/all.70166
Christian Radauer,Gabriele Gadermaier,Richard E Goodman,Alain Jacquet,Uta Jappe,Andreas L Lopata,Anna Pomés,Monika Raulf,Keity S Santos,Josefina Zakzuk,Yuzhu Zhang,Joana Vitte,
The WHO/IUIS Allergen Nomenclature Sub-Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024. The sub-committee assigned names to 112 new allergens with 124 isoallergens/variants as well as 26 new isoallergens/variants of previously named allergens. Most new allergens were respiratory allergens from animals (35 allergens) and plants (25) as well as food allergens from animals (22) and plants (17). Many newly identified allergens reflect globalized allergen exposure and growing research activities outside of Western countries. This is illustrated by allergens from the tropical mite Blomia tropicalis, pollen allergens from tree and weed species native to Asia, and food allergens from regionally important foods such as mango, seafood, silkworm pupae, and natto. The allergen profiles of most relevant sources are well established, but gaps in our knowledge remain, particularly regarding allergens important for populations outside of Europe and North America. The still growing number of known allergens highlights the importance of a consistent, unambiguous allergen nomenclature that evolves with clinical demands and scientific discovery and supports efforts to close existing knowledge gaps.
世卫组织/美国过敏原命名小组委员会是一个国际专家机构,通过为研究人员提交的新鉴定的过敏原指定正式名称,维持致敏蛋白的系统命名。在这里,我们总结了2021年至2024年间批准的新过敏原的数据。小组委员会命名了112个新的过敏原,其中包括124个等过敏原/变异体,以及26个新的等过敏原/变异体。大多数新发现的过敏原是来自动物(35个)和植物(25个)的呼吸道过敏原,以及来自动物(22个)和植物(17个)的食物过敏原。许多新发现的过敏原反映了全球化的过敏原暴露和西方国家以外日益增长的研究活动。这可以从热带螨(Blomia tropicalis)的过敏原、亚洲原生树种和杂草的花粉过敏原、以及地区性重要食物(如芒果、海鲜、蚕蛹和纳豆)的食物过敏原中得到证明。大多数相关来源的过敏原概况已经建立,但我们的知识仍然存在差距,特别是关于对欧洲和北美以外人群重要的过敏原。随着临床需求和科学发现的发展,已知过敏原的数量仍在不断增加,这凸显了一致、明确的过敏原命名法的重要性,并支持缩小现有知识差距的努力。
{"title":"New Allergens Approved by the WHO/IUIS Allergen Nomenclature Sub-Committee in 2021-2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report.","authors":"Christian Radauer,Gabriele Gadermaier,Richard E Goodman,Alain Jacquet,Uta Jappe,Andreas L Lopata,Anna Pomés,Monika Raulf,Keity S Santos,Josefina Zakzuk,Yuzhu Zhang,Joana Vitte, ","doi":"10.1111/all.70166","DOIUrl":"https://doi.org/10.1111/all.70166","url":null,"abstract":"The WHO/IUIS Allergen Nomenclature Sub-Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024. The sub-committee assigned names to 112 new allergens with 124 isoallergens/variants as well as 26 new isoallergens/variants of previously named allergens. Most new allergens were respiratory allergens from animals (35 allergens) and plants (25) as well as food allergens from animals (22) and plants (17). Many newly identified allergens reflect globalized allergen exposure and growing research activities outside of Western countries. This is illustrated by allergens from the tropical mite Blomia tropicalis, pollen allergens from tree and weed species native to Asia, and food allergens from regionally important foods such as mango, seafood, silkworm pupae, and natto. The allergen profiles of most relevant sources are well established, but gaps in our knowledge remain, particularly regarding allergens important for populations outside of Europe and North America. The still growing number of known allergens highlights the importance of a consistent, unambiguous allergen nomenclature that evolves with clinical demands and scientific discovery and supports efforts to close existing knowledge gaps.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"13 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145619808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein Glycosylation: An Emerging Regulator of Allergic Diseases. 蛋白糖基化:变态反应性疾病的新兴调节因子。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-11-28 DOI: 10.1111/all.70171
Pan Li,Xianghong Wang,Ming Zeng,Zheng Liu
Type 2 (T2) inflammation is central to allergic disorders. Glycosylation, a post-translational modification, is emerging as a pivotal regulator in T2 inflammation and associated allergic diseases. This review synthesizes current knowledge on glycosylation patterns of key T2 inflammation players, including cytokines, immunoglobulins (e.g., IgE, IgG4) and their receptors, STAT6, mucins, and CTLA-4. We detail how site-specific glycosylation fine-tunes cytokine-receptor interactions, alters signaling pathways, and stabilizes proteins, thereby dictating their bioactivity. Moreover, we examine the enzymatic machinery orchestrating these glycosylation events and the regulatory factors modulating their activity in the context of T2 inflammation. By leveraging these mechanistic insights, we highlight how glycosylation aberrations contribute to food allergy, eosinophilic esophagitis, asthma, allergic rhinitis, and atopic dermatitis, while allergen immunotherapy exploits glycosylation reprogramming (e.g., sialylated IgG4 induction) to restore immune tolerance. Furthermore, we explore the diagnostic and prognostic potential of glycosylation patterns in predicting disease severity and allergen immunotherapy responsiveness, while underscoring the therapeutic promise of targeting glycosylation enzymes or glycan-immune receptor interactions to mitigate T2 inflammation-driven pathologies. A deeper understanding of glycosylation dynamics in T2 inflammation not only enhances our grasp of disease pathogenesis but also opens new avenues for innovative therapeutic interventions.
2型(T2)炎症是过敏性疾病的核心。糖基化,一种翻译后修饰,正在成为T2炎症和相关过敏性疾病的关键调节因子。这篇综述综合了目前关于T2炎症关键参与者糖基化模式的知识,包括细胞因子、免疫球蛋白(如IgE、IgG4)及其受体、STAT6、粘蛋白和CTLA-4。我们详细介绍了位点特异性糖基化如何微调细胞因子与受体的相互作用,改变信号通路,并稳定蛋白质,从而决定它们的生物活性。此外,我们研究了在T2炎症背景下协调这些糖基化事件的酶机制和调节其活性的调节因子。通过利用这些机制的见解,我们强调糖基化异常如何导致食物过敏、嗜酸性食管炎、哮喘、过敏性鼻炎和特应性皮炎,而过敏原免疫疗法利用糖基化重编程(例如,唾液化IgG4诱导)来恢复免疫耐受。此外,我们探讨了糖基化模式在预测疾病严重程度和过敏原免疫治疗反应性方面的诊断和预后潜力,同时强调了靶向糖基化酶或聚糖-免疫受体相互作用以减轻T2炎症驱动病理的治疗前景。对T2炎症中糖基化动力学的深入了解不仅增强了我们对疾病发病机制的掌握,而且为创新的治疗干预开辟了新的途径。
{"title":"Protein Glycosylation: An Emerging Regulator of Allergic Diseases.","authors":"Pan Li,Xianghong Wang,Ming Zeng,Zheng Liu","doi":"10.1111/all.70171","DOIUrl":"https://doi.org/10.1111/all.70171","url":null,"abstract":"Type 2 (T2) inflammation is central to allergic disorders. Glycosylation, a post-translational modification, is emerging as a pivotal regulator in T2 inflammation and associated allergic diseases. This review synthesizes current knowledge on glycosylation patterns of key T2 inflammation players, including cytokines, immunoglobulins (e.g., IgE, IgG4) and their receptors, STAT6, mucins, and CTLA-4. We detail how site-specific glycosylation fine-tunes cytokine-receptor interactions, alters signaling pathways, and stabilizes proteins, thereby dictating their bioactivity. Moreover, we examine the enzymatic machinery orchestrating these glycosylation events and the regulatory factors modulating their activity in the context of T2 inflammation. By leveraging these mechanistic insights, we highlight how glycosylation aberrations contribute to food allergy, eosinophilic esophagitis, asthma, allergic rhinitis, and atopic dermatitis, while allergen immunotherapy exploits glycosylation reprogramming (e.g., sialylated IgG4 induction) to restore immune tolerance. Furthermore, we explore the diagnostic and prognostic potential of glycosylation patterns in predicting disease severity and allergen immunotherapy responsiveness, while underscoring the therapeutic promise of targeting glycosylation enzymes or glycan-immune receptor interactions to mitigate T2 inflammation-driven pathologies. A deeper understanding of glycosylation dynamics in T2 inflammation not only enhances our grasp of disease pathogenesis but also opens new avenues for innovative therapeutic interventions.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"4 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145613350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen-Specific Immune Responses. 口服免疫治疗诱导lncRNA表达转移,调节过敏原特异性免疫反应。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-11-28 DOI: 10.1111/all.70173
Olivia Liong,Kati Palosuo,Victoria Hinkkanen,Vittorio Fortino,Mika J Mäkelä,Piia Karisola
BACKGROUNDPreviously, we reported the success of egg oral immunotherapy (OIT) in liberating most participants from dietary restrictions. The diminishing symptoms and declining inflammation were accompanied by differential expression of genes in peripheral blood mononuclear cells (PBMCs) of 50 egg-allergic children following 8 months of OIT.METHODSHere, we explore the impact of OIT on long non-coding RNA (lncRNA) expression and its downstream effects on allergen-specific immune response with the help of PBMC transcriptome, co-expression gene module identification, pathway enrichment analyses and in vitro stimulation in both PBMC and THP1 cells.RESULTSWe observed 17 lncRNAs which correlated positively with genes involved in IL-13, IL-4, and IL-10 signaling pathways. The same set of lncRNAs correlated negatively with genes playing a role in neutrophil degranulation, phagosome formation, and pyroptosis signaling. The expression of one of the most important lncRNAs, LOC644727, was found to align with CXCL8 expression in egg extract-stimulated PBMCs and LPS-stimulated THP1-derived macrophages.CONCLUSIONSOur results highlight the involvement of lncRNA in the regulation of gene expression during OIT. LOC644727 may serve as a potential marker for inflammatory responses and it may offer a therapeutic target for future desensitization protocols.
之前,我们报道了鸡蛋口服免疫疗法(OIT)成功地将大多数参与者从饮食限制中解放出来。50例鸡蛋过敏儿童在接受OIT治疗8个月后,其外周血单个核细胞(PBMCs)中基因的差异表达伴随着症状的减轻和炎症的减轻。方法通过PBMC和THP1细胞的转录组、共表达基因模块鉴定、途径富集分析和体外刺激,探讨OIT对长链非编码RNA (lncRNA)表达的影响及其对过敏原特异性免疫反应的下游影响。结果观察到17个与IL-13、IL-4和IL-10信号通路相关的lncrna。同一组lncRNAs与参与中性粒细胞脱粒、吞噬体形成和焦亡信号传导的基因负相关。在蛋提取物刺激的pbmc和lps刺激的thp1源性巨噬细胞中,最重要的lncrna之一LOC644727的表达与CXCL8表达一致。结论lncRNA参与了OIT过程中基因表达的调控。LOC644727可能作为炎症反应的潜在标记物,并可能为未来的脱敏方案提供治疗靶点。
{"title":"Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen-Specific Immune Responses.","authors":"Olivia Liong,Kati Palosuo,Victoria Hinkkanen,Vittorio Fortino,Mika J Mäkelä,Piia Karisola","doi":"10.1111/all.70173","DOIUrl":"https://doi.org/10.1111/all.70173","url":null,"abstract":"BACKGROUNDPreviously, we reported the success of egg oral immunotherapy (OIT) in liberating most participants from dietary restrictions. The diminishing symptoms and declining inflammation were accompanied by differential expression of genes in peripheral blood mononuclear cells (PBMCs) of 50 egg-allergic children following 8 months of OIT.METHODSHere, we explore the impact of OIT on long non-coding RNA (lncRNA) expression and its downstream effects on allergen-specific immune response with the help of PBMC transcriptome, co-expression gene module identification, pathway enrichment analyses and in vitro stimulation in both PBMC and THP1 cells.RESULTSWe observed 17 lncRNAs which correlated positively with genes involved in IL-13, IL-4, and IL-10 signaling pathways. The same set of lncRNAs correlated negatively with genes playing a role in neutrophil degranulation, phagosome formation, and pyroptosis signaling. The expression of one of the most important lncRNAs, LOC644727, was found to align with CXCL8 expression in egg extract-stimulated PBMCs and LPS-stimulated THP1-derived macrophages.CONCLUSIONSOur results highlight the involvement of lncRNA in the regulation of gene expression during OIT. LOC644727 may serve as a potential marker for inflammatory responses and it may offer a therapeutic target for future desensitization protocols.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"68 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145613349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplacental Antimicrobial Antibodies and Childhood Asthma: Maternal Nativity as an Upstream Factor 经胎盘抗菌抗体和儿童哮喘:母体出生作为上游因素
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2025-11-27 DOI: 10.1111/all.70167
Xiumei Hong, Kari C. Nadeau, Pamela Frischmeyer‐Guerrerio, Guoying Wang, August F. Jernbom, Shuai Li, Ni Zhao, William R. Morgenlander, Julia W. Angkeow, Manju Thakar, Colleen Pearson, William G. Adams, H. Benjamin Larman, Hongkai Ji, Xiaobin Wang
Background Early‐life microbial exposure to microbes may play a role in asthma development. This study tests the hypothesis that mothers born in low‐income countries might have been exposed to diverse microbes—leading to greater diversity and higher levels of transplacental anti‐microbial antibodies, thereby conferring protection against asthma in offspring. Methods In the prospective Boston Birth Cohort, IgG antibody reactome against microbes (2740 species; 1311 genera) was profiled in cord blood, using Phage ImmunoPrecipitation Sequencing. Multinomial regression models were applied to examine the associations of cord blood IgG reactome with child risk of physician‐diagnosed atopy and asthma. Mediation analysis was performed to examine the inter‐relationships among maternal nativity, IgG reactome and risk of developing childhood asthma. Results This report included 943 mother–child dyads enrolled at birth and followed prospectively. Compared to children of US‐born mothers, children of foreign‐born mothers had a lower prevalence of asthma (17.5% vs. 30.5%) and greater diversity of cord blood IgG antibodies against hundreds of microbes (FDR < 0.05). Cord blood seropositivity to peptides or proteins from 6 microbes was inversely associated with the risk of asthma in children, and children with more seropositivity to these microbes were at a lower risk of developing asthma ( p < 0.001). IgG seropositivity to A. actinomycetemcomitans , H. pylori , S. flexneri , and T. parva each mediated 17%–62% of the association between maternal nativity and child risk of asthma. Conclusion In this US prospective birth cohort, maternal transplacental IgG reactivity to four microbes ( A. actinomycetemcomitans , H. pylori , S. flexneri and T. parva ) was associated with a lower risk of childhood asthma, and partly explains the lower risk of asthma in children of mothers born outside the US.
早期接触微生物可能在哮喘发展中起作用。本研究验证了这样一种假设,即出生在低收入国家的母亲可能接触过多种微生物,从而导致更大的多样性和更高水平的经胎盘抗微生物抗体,从而为后代提供抗哮喘的保护。方法在前瞻性波士顿出生队列中,使用噬菌体免疫沉淀测序(Phage ImmunoPrecipitation Sequencing)分析了脐带血中抗微生物(2740种,1311属)的IgG抗体反应组。采用多项回归模型检验脐带血IgG反应组与儿童医生诊断的特应性和哮喘风险的关系。采用中介分析来检验产妇出生、IgG反应和儿童哮喘发病风险之间的相互关系。结果本报告纳入943对出生时登记的母子二人组,并进行前瞻性随访。与美国出生母亲的孩子相比,外国出生母亲的孩子哮喘患病率较低(17.5%对30.5%),并且针对数百种微生物的脐带血IgG抗体多样性更高(FDR < 0.05)。脐带血对6种微生物多肽或蛋白质的血清阳性与儿童哮喘风险呈负相关,对这些微生物血清阳性越多的儿童患哮喘的风险越低(p < 0.001)。放线菌、幽门螺杆菌、弗氏沙门氏菌和微小梭菌血清IgG阳性分别介导了产妇出生与儿童哮喘风险之间17%-62%的关联。结论:在美国的前瞻性出生队列中,母亲经胎盘IgG对四种微生物(放线菌、幽门螺旋杆菌、弗氏杆菌和微小梭菌)的反应性与儿童哮喘风险较低有关,这在一定程度上解释了在美国以外出生的母亲的孩子哮喘风险较低的原因。
{"title":"Transplacental Antimicrobial Antibodies and Childhood Asthma: Maternal Nativity as an Upstream Factor","authors":"Xiumei Hong, Kari C. Nadeau, Pamela Frischmeyer‐Guerrerio, Guoying Wang, August F. Jernbom, Shuai Li, Ni Zhao, William R. Morgenlander, Julia W. Angkeow, Manju Thakar, Colleen Pearson, William G. Adams, H. Benjamin Larman, Hongkai Ji, Xiaobin Wang","doi":"10.1111/all.70167","DOIUrl":"https://doi.org/10.1111/all.70167","url":null,"abstract":"Background Early‐life microbial exposure to microbes may play a role in asthma development. This study tests the hypothesis that mothers born in low‐income countries might have been exposed to diverse microbes—leading to greater diversity and higher levels of transplacental anti‐microbial antibodies, thereby conferring protection against asthma in offspring. Methods In the prospective Boston Birth Cohort, IgG antibody reactome against microbes (2740 species; 1311 genera) was profiled in cord blood, using Phage ImmunoPrecipitation Sequencing. Multinomial regression models were applied to examine the associations of cord blood IgG reactome with child risk of physician‐diagnosed atopy and asthma. Mediation analysis was performed to examine the inter‐relationships among maternal nativity, IgG reactome and risk of developing childhood asthma. Results This report included 943 mother–child dyads enrolled at birth and followed prospectively. Compared to children of US‐born mothers, children of foreign‐born mothers had a lower prevalence of asthma (17.5% vs. 30.5%) and greater diversity of cord blood IgG antibodies against hundreds of microbes (FDR &lt; 0.05). Cord blood seropositivity to peptides or proteins from 6 microbes was inversely associated with the risk of asthma in children, and children with more seropositivity to these microbes were at a lower risk of developing asthma ( <jats:italic>p</jats:italic> &lt; 0.001). IgG seropositivity to <jats:italic> <jats:styled-content style=\"fixed-case\">A. actinomycetemcomitans</jats:styled-content> , <jats:styled-content style=\"fixed-case\">H. pylori</jats:styled-content> </jats:italic> , <jats:styled-content style=\"fixed-case\"> <jats:italic>S. flexneri</jats:italic> </jats:styled-content> , and <jats:styled-content style=\"fixed-case\"> <jats:italic>T. parva</jats:italic> </jats:styled-content> each mediated 17%–62% of the association between maternal nativity and child risk of asthma. Conclusion In this US prospective birth cohort, maternal transplacental IgG reactivity to four microbes ( <jats:styled-content style=\"fixed-case\"> <jats:italic>A. actinomycetemcomitans</jats:italic> </jats:styled-content> , <jats:styled-content style=\"fixed-case\"> <jats:italic>H. pylori</jats:italic> </jats:styled-content> , <jats:italic> <jats:styled-content style=\"fixed-case\">S. flexneri</jats:styled-content> and <jats:styled-content style=\"fixed-case\">T. parva</jats:styled-content> </jats:italic> ) was associated with a lower risk of childhood asthma, and partly explains the lower risk of asthma in children of mothers born outside the US.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"97 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145609105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1